Showing 4691-4700 of 9848 results for "".
- FDA Clears Venus Versa for 20-Plus Common Clinical Indicationshttps://practicaldermatology.com/news/fda-clears-venus-versatm-for-20-plus-common-clinical-indications/2458632/The U.S. Food and Drug Administration cleared Venus Concept’s Venus Versa™ system for skin rejuvenation, hair removal, facial wrinkles and rhytides, skin resurfacing, pigmented and vascular lesions, and acne vulgaris.
- Valeant Pharmaceuticals Comments On Management Changehttps://practicaldermatology.com/news/valeant-pharmaceuticals-comments-on-management-change/2458668/Valeant Pharmaceuticals International, Inc. today issued the following comments in response to inquiries from investors regarding Deb Jorn's departure from Valeant.
- Grooming Habits, Products May Affect Alopecia Riskhttps://practicaldermatology.com/news/grooming-habits-products-may-affect-alopecia-risk/2458671/Environmental factors --including weathering and grooming habits – may play a role in causing age-related alopecia, according to a new report in the International Journal of Women’s Dermatolog
- Neutrogena® Launches First-Ever Global Beauty Campaignhttps://practicaldermatology.com/news/neutrogena-launches-first-ever-global-beauty-campaign/2458684/Neutrogena® is set to debut their first-ever global campaign: “Neutrogena. See What’s Possible.™” A commercial voiced by Brand Ambassador and creative consultant Kerry Washington will fe
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- ZELTIQ® Taps Todd Zavodnick as New President, Internationalhttps://practicaldermatology.com/news/zeltiq-taps-todd-zavodnick-as-new-president-international/2458708/Todd Zavodnick is the new President, International of ZELTIQ®. Mr. Zavodnick will be responsible for driving the company’s international growth and expansion. He rec
- Gary D. Monheit, MD Wins Top ASDS Honorhttps://practicaldermatology.com/news/gary-d-monheit-md-wins-top-asds-honor/2459040/Gary D. Monheit, MD is the “very honored” 2014 recipient of the American Society for Dermatologic Surgery's highest honor: the Samuel J. Stegman, MD, Award for D
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring s
- Restoration's ARTAS Earns Edison Gold Medal for Innovationhttps://practicaldermatology.com/news/20130430-restorations_artas_earns_edison_gold_medal_for_innovation/2459554/Restoration Robotics, Inc.'s ARTAS® System was honored with the Gold medal at the 26th Edison Awards, the international awards ceremony honoring innovators and innovation, in the science/medical category. The Edison Awards celebrate human creati
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM